Skip to main content

Security report for atbtherapeutics.com

ATB Therapeutics · Healthcare · Belgium

Medium risk. 6 critical or high findings in Security headers, GDPR outside view and 1 other check.

Security score

54/100

Risk levelMedium

0–100, higher is better. How it is calculated

ATB Therapeutics is a pioneering biotechnology company specializing in novel antibody therapies targeting oncology and auto-immune diseases. Their innovative atbody format and plant-based manufacturing technology position them as an emerging player in the biotech sector, focusing on unmet clinical needs. The company operates primarily in Belgium and has a small but focused organizational size, with a domain age consistent with their founding year of 2017. The website reflects a professional and consistent brand image, targeting healthcare professionals, investors, and partners. Technically, the website is built on modern web technologies including React, uses slick carousel for UI elements, and integrates Google Analytics for user tracking. Hosting is provided by One.com A/S, and the site is mobile-optimized with good performance. However, there is room for improvement in accessibility and SEO optimization. From a security perspective, the site uses HTTPS with good SSL configuration but lacks important security headers and published security policies. No cookie consent mechanism is present, which impacts GDPR compliance. No incident response or vulnerability disclosure information is available, indicating a potential gap in security transparency. Overall, the website is trustworthy and professional but would benefit from enhanced security practices and privacy compliance measures to strengthen its risk posture and user trust.

Scanned

NIS2 and GDPR posture

GDPR outside view
53/ 100 · Medium
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

6 findings rated critical or high. Fix these first.

  1. Security headers

    Security headers are instructions your web server sends to every visitor’s browser. Missing ones leave visitors more exposed to attacks such as clickjacking and injected scripts.

    • High

      Missing Strict-Transport-Security header

      Forces HTTPS connections

      What to do: Add "Strict-Transport-Security: max-age=31536000; includeSubDomains; preload"

      • CWE-319
      • OWASP A04:2025
      • ASVS V3.4.1
    • High

      Missing X-Frame-Options header

      Prevents clickjacking attacks

      What to do: Add "X-Frame-Options: DENY" or "X-Frame-Options: SAMEORIGIN"

    • High

      Missing Content-Security-Policy header

      Controls resources the browser is allowed to load

      What to do: Implement a Content-Security-Policy appropriate for your application

      • ASVS V3.4.3
      • OWASP Secure Headers: OWASP Secure Headers Project recommends Content-Security-Policy: default-src 'self'; form-action 'self'; base-uri 'self'; object-src 'none';…

  2. GDPR outside view

    These are the privacy signals visitors and data protection authorities look for under GDPR.

    • High

      No Cookie Policy found

      GDPR requires clear information about cookie usage

      What to do: Add a dedicated cookie policy explaining cookie usage and purposes

    • High

      No Cookie Consent Banner found

      GDPR requires explicit consent for non-essential cookies

      What to do: Implement a cookie consent banner that appears on first visit

Need hands-on remediation? Email guard@offseq.com

Keep watching atbtherapeutics.com

This scan found 26 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. The full timeline opens with your unlock code.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
72
Security headers
15
Email security
85
DNS health
60
Network security
40
GDPR outside view
53
Average
54

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

ATB Therapeutics holds a unique market position with its proprietary antibody payload technology and disruptive plant-based manufacturing platform. Their business model centers on R&D and therapeutic development for cancer and autoimmune diseases, targeting healthcare providers and investors. The company demonstrates growth through recent press releases and funding announcements. Their partnership ecosystem includes a web design partner but no other explicit business partners or subsidiaries are identified. The company maintains active social media presence on LinkedIn and Twitter, supporting investor relations and brand awareness. Revenue streams likely derive from licensing, partnerships, and eventual product commercialization. Strategic observations suggest a focus on innovation and pipeline expansion in solid tumors, positioning them well for future growth.

Security posture

The current security maturity level is moderate. The website enforces HTTPS and avoids exposing sensitive data, which is positive. However, the absence of security headers such as Content-Security-Policy, X-Frame-Options, and X-Content-Type-Options reduces protection against common web attacks. The lack of published security policies, incident response contacts, and vulnerability disclosure mechanisms indicates limited transparency and preparedness. GDPR compliance is partial due to missing cookie consent and explicit privacy compliance indicators. No vulnerabilities or malicious content were detected in the analysis. The security culture appears nascent, with opportunities to improve user trust and regulatory adherence through enhanced policies and technical controls.

Recommendations

  1. Implement comprehensive security headers including Content-Security-Policy, X-Frame-Options, and X-Content-Type-Options to mitigate common web vulnerabilities.
  2. Deploy a cookie consent banner and mechanism to comply with GDPR and enhance user privacy transparency.
  3. Publish a detailed security policy and incident response contact information to improve transparency and readiness.
  4. Regularly audit and update third-party scripts and libraries to avoid vulnerabilities.
  5. Consider enabling DNSSEC for the domain to strengthen DNS security and prevent spoofing.

Contact details published on the site

Addresses
Legal name
ATB Therapeutics
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
ATB Therapeutics
Description
A pioneering biotechnology company dedicated to novel antibody therapies for oncology and auto-immune disease. They focus on innovative antibody payload technology and plant-based manufacturing technology to address unmet clinical needs in cancer and autoimmune diseases.
Key services
Antibody payload technology development, Plant-based manufacturing technology, Therapeutic solutions for cancer and auto-immune diseases
Content quality
good
Branding
consistent

Technology

Stack
React, Slick Carousel, Animate.css, Google Analytics
Frameworks
React
Performance
moderate
Mobile
good
Accessibility
basic
SEO
basic

Security

Observed score
75/100
Good practices seen
  • HTTPS enabled
  • No exposed sensitive data in HTML
  • No visible vulnerable libraries

Analytics and tracking

Services
Google Analytics, Google Tag Manager
Tracking level
moderate
Privacy practices
basic

Advertising

Transparency
basic

Site quality

Design
good
User experience
good
Content relevance
good
Navigation
good
Professionalism
good
Trustworthiness
high

Key observations

  1. Website is professionally designed and well-structured.
  2. Clear focus on biotechnology and antibody therapies.
  3. Contact information is prominently displayed with physical addresses and email.
  4. No phone numbers explicitly provided.
  5. No cookie consent banner or mechanism detected.
  6. No explicit security or incident response policies published.
  7. Use of modern web technologies and analytics tools.
  8. No signs of malicious or suspicious content.
  9. WHOIS data supports legitimacy and business consistency.
Technical notes

Notes

The website infrastructure is modern and built on React with slick carousel and animate.css for UI effects. Hosting is via One.com A/S, a reputable provider. Performance is moderate with good mobile optimization and basic accessibility features. SEO optimization is basic with meta tags present but no advanced structured data or Open Graph tags detected. The site uses Google Analytics and Google Tag Manager for tracking, indicating moderate user tracking. Technical debt appears low but improvements in accessibility and SEO could enhance user experience and search visibility. The custom CMS backend is inferred from asset URLs, suggesting tailored content management. Overall, the technical implementation supports the business goals but could benefit from modernization in security and privacy features.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with atbtherapeutics.com. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review atbtherapeutics.com.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.